Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
BMRA Stock Overview
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide.
Biomerica Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.99 |
52 Week High | US$7.38 |
52 Week Low | US$2.65 |
Beta | -0.50 |
1 Month Change | -10.48% |
3 Month Change | -33.70% |
1 Year Change | -25.06% |
3 Year Change | 14.12% |
5 Year Change | 10.23% |
Change since IPO | -14.57% |
Recent News & Updates
Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable
Despite strong share price growth of 66% for Biomerica, Inc. ( NASDAQ:BMRA ) over the last few years, earnings growth...
Shareholder Returns
BMRA | US Medical Equipment | US Market | |
---|---|---|---|
7D | -3.9% | 3.5% | 1.7% |
1Y | -25.1% | -25.7% | -20.4% |
Return vs Industry: BMRA underperformed the US Medical Equipment industry which returned -24% over the past year.
Return vs Market: BMRA underperformed the US Market which returned -18.8% over the past year.
Price Volatility
BMRA volatility | |
---|---|
BMRA Average Weekly Movement | 9.9% |
Medical Equipment Industry Average Movement | 10.4% |
Market Average Movement | 8.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BMRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: BMRA's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1971 | 66 | Zack Irani | https://www.biomerica.com |
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company’s diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient’s body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories.
Biomerica Fundamentals Summary
BMRA fundamental statistics | |
---|---|
Market Cap | US$38.56m |
Earnings (TTM) | -US$3.51m |
Revenue (TTM) | US$14.62m |
2.6x
P/S Ratio-11.0x
P/E RatioIs BMRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BMRA income statement (TTM) | |
---|---|
Revenue | US$14.62m |
Cost of Revenue | US$12.12m |
Gross Profit | US$2.50m |
Other Expenses | US$6.01m |
Earnings | -US$3.51m |
Last Reported Earnings
Feb 28, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.27 |
Gross Margin | 17.09% |
Net Profit Margin | -23.98% |
Debt/Equity Ratio | 0% |
How did BMRA perform over the long term?
See historical performance and comparisonValuation
Is BMRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BMRA?
Other financial metrics that can be useful for relative valuation.
What is BMRA's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | US$38.56m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2x |
Enterprise Value/EBITDA | -8.8x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BMRA's PS Ratio compare to its peers?
BMRA PS Ratio vs Peers |
---|
Company | PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 8.6x | ||
ECOR electroCore | 5.9x | 38.8% | US$36.3m |
BIEL BioElectronics | 15.8x | n/a | US$23.5m |
PEYE Precision Optics Corporation | 2.2x | n/a | US$30.1m |
AWH Aspira Women's Health | 10.6x | 39.0% | US$76.4m |
BMRA Biomerica | 2.6x | n/a | US$38.6m |
Price-To-Sales vs Peers: BMRA is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (8.6x).
Price to Earnings Ratio vs Industry
How does BMRA's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: BMRA is good value based on its Price-To-Sales Ratio (2.6x) compared to the US Medical Equipment industry average (4x)
Price to Sales Ratio vs Fair Ratio
What is BMRA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 2.6x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BMRA's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of BMRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BMRA ($2.99) is trading below our estimate of fair value ($13.34)
Significantly Below Fair Value: BMRA is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BMRA's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Biomerica forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
16.1%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biomerica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether Biomerica is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
Past Performance
How has Biomerica performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-34.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BMRA is currently unprofitable.
Growing Profit Margin: BMRA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BMRA is unprofitable, and losses have increased over the past 5 years at a rate of 34.1% per year.
Accelerating Growth: Unable to compare BMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BMRA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: BMRA has a negative Return on Equity (-35.93%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Biomerica's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BMRA's short term assets ($15.2M) exceed its short term liabilities ($6.7M).
Long Term Liabilities: BMRA's short term assets ($15.2M) exceed its long term liabilities ($1.1M).
Debt to Equity History and Analysis
Debt Level: BMRA is debt free.
Reducing Debt: BMRA had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BMRA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BMRA is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 28.3% per year.
Discover healthy companies
Dividend
What is Biomerica current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BMRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BMRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BMRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BMRA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BMRA has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.8yrs
Average management tenure
CEO
Zack Irani (55 yo)
25.17yrs
Tenure
US$488,334
Compensation
Mr. Zackary S. Irani, also known as Zack, has been Chairman of the Board and Chief Executive Officer of Biomerica Inc. since April 29, 1997 and served as its President. Mr. Irani serves as the President an...
CEO Compensation Analysis
Compensation vs Market: Zack's total compensation ($USD488.33K) is below average for companies of similar size in the US market ($USD752.76K).
Compensation vs Earnings: Zack's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: BMRA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
Experienced Board: BMRA's board of directors are considered experienced (5.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.
Top Shareholders
Company Information
Biomerica, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Biomerica, Inc.
- Ticker: BMRA
- Exchange: NasdaqCM
- Founded: 1971
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$38.556m
- Shares outstanding: 12.85m
- Website: https://www.biomerica.com
Number of Employees
Location
- Biomerica, Inc.
- 17571 Von Karman Avenue
- Irvine
- California
- 92614
- United States
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/28 00:00 |
End of Day Share Price | 2022/06/28 00:00 |
Earnings | 2022/02/28 |
Annual Earnings | 2021/05/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.